세계의 IPS 세포 유래 오가노이드 시장 : 유형, 용도, 최종사용자, 지역별 예측(-2032년)

Global IPS Cell Derived Organoids Market Research Report Information by Type (Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids, and Others), by Application (Drug Discovery and Development, Disease Modelling, and Regenerative Medicine), by End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Contract Research Organization), and by Region (North America, Europe, Asia-Pacific, and Rest of the World Forecast till 2032

An Overview of the Market

IPS Cell Derived Organoids Market size was valued at USD 0.44 billion in 2023. The IPS Cell Derived Organoids Market industry is projected to grow from USD 0.51 billion in 2024 to USD 1.89 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 17.8% during the forecast period (2024 - 2032).

IPS cell-derived organoids market represent a revolutionary advancement in biomedical research and drug development. These miniature, three-dimensional tissue models, generated from induced pluripotent stem cells (iPSCs), offer unprecedented opportunities for studying human physiology, disease mechanisms, and drug efficacy. Organoids are used in various applications, including disease modelling, drug discovery, personalized medicine, and regenerative therapies. The iPS cell-derived organoids market is poised for substantial growth, driven by technological advancements, increasing demand for personalized medicine, and expanding applications in drug discovery and regenerative medicine. However, overcoming technical, regulatory, and ethical challenges will be crucial for realizing the full potential of this transformative technology.

Market segmentation insights

The IPS Cell Derived Organoids Market segmentation, based on type, includes Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids, and Others.

The IPS Cell Derived Organoids Market segmentation, based on application, includes drug discovery and development, disease modelling, and regenerative medicine.

Regional Insights

The IPS Cell Derived Organoids market in America boasts a robust research infrastructure, substantial investments in life sciences, and a thriving biotechnology industry. North America is home to several top-tier universities and research centers that are at the forefront of stem cell research. This region has seen substantial investments from both public and private sectors aimed at advancing the development and application of iPS cell-derived organoids. The well-established healthcare systems in North America facilitate the adoption of advanced medical technologies. The presence of sophisticated laboratory facilities and skilled professionals further supports market growth. The region's inclination towards technological adoption has fostered the development and application of organoid-based platforms. Supportive regulatory frameworks encourage investments in organoid research and development.

Europe IPS Cell Derived Organoids market accounted for the second-largest market share due to region's emphasis on healthcare, coupled with a strong scientific community, drives the market. Furthermore, the Germany IPS Cell Derived Organoids provider attributed to hold the largest market share, and the France IPS Cell Derived Organoids providers is projected be the fastest growing market in the Europe region.

The Asia-Pacific IPS Cell Derived Organoids market is expected to be the fastest growing from 2023 to 2032 due to increasing investments in biomedical research, growing healthcare expenditure, and a rising prevalence of chronic diseases can support IPS Cell Derived Organoids development.

Prominent Participants

Key Companies in the IPS Cell Derived Organoids market includes ACROBiosystems (US), Miltenyi Biotec (Germany), ThermoFisher Scientific (US), STEMCELL Technologies (Canada), Bio-Techne (US), Merck KGaA (Germany), Molecular Devices, LLC (US), Corning Incorporated (US), Promega Corporation (US), and Creative Bioarray (US).

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
  • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TECHNIQUE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 GROWING ADOPTION OF PERSONALIZED DRUGS
  • 4.2.2 RISING PREVALENCE OF CHRONIC DISEASES
  • 4.2.3 ADVANCEMENTS IN STEM CELL RESEARCH
  • 4.2.4 DRIVER IMPACT ANALYSIS
• 4.3 RESTRAINTS
  • 4.3.1 HIGH COST OF ORGANOID DEVELOPMENT AND MAINTENANCE
  • 4.3.2 REGULATORY HURDLES AND STANDARDIZATION
  • 4.3.3 RESTRAINT IMPACT ANALYSIS
• 4.4 OPPORTUNITY
  • 4.4.1 DEVELOPMENT OF MORE COMPLEX AND FUNCTIONAL ORGANOIDS
  • 4.4.2 EXPANSION OF APPLICATIONS IN DRUG DISCOVERY AND TOXICOLOGY
• 4.5 IMPACT ANALYSIS OF COVID -
  • 4.5.1 IMPACT ON OVERALL HEALTH INDUSTRY
  • 4.5.2 IMPACT ON GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET
  • 4.5.3 IMPACT ON SUPPLY CHAIN OF IPS CELL-DERIVED ORGANOIDS
  • 4.5.4 IMPACT ON MARKET DEMAND OF IPS CELL-DERIVED ORGANOIDS
  • 4.5.5 IMPACT ON PRICING OF IPS CELL-DERIVED ORGANOIDS

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 INTENSITY OF RIVALRY
• 5.2 SUPPLY CHAIN ANALYSIS
  • 5.2.1 RAW MATERIAL
  • 5.2.2 PRODUCTION PROCESS
  • 5.2.3 DISTRIBUTION
  • 5.2.4 END USER

6 GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE

• 6.1 OVERVIEW
• 6.2 BRAIN
• 6.3 HEART
• 6.4 LUNG
• 6.5 LIVER
• 6.6 KIDNEY
• 6.7 OTHERS

7 GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION

• 7.1 OVERVIEW
• 7.2 DRUG DISCOVERY AND DEVELOPMENT
• 7.3 DISEASE MODELLING
• 7.4 REGENERATIVE MEDICINE

8 GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER

• 8.1 OVERVIEW
• 8.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
• 8.3 ACADEMIC AND RESEARCH INSTITUTES
• 8.4 CONTRACT RESEARCH ORGANIZATION

9 GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET, BY REGION

• 9.1 OVERVIEW
  • 9.1.1 GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET, BY REGION, 2020-2032
• 9.2 NORTH AMERICA
  • 9.2.1 NORTH AMERICA: IPS CELL-DERIVED ORGANOIDS MARKET, BY COUNTRY, 2020-2032
• 9.3 EUROPE
  • 9.3.1 EUROPE: IPS CELL-DERIVED ORGANOIDS MARKET, BY COUNTRY, 2020-2032
• 9.4 ASIA PACIFIC
  • 9.4.1 ASIA PACIFIC: IPS CELL-DERIVED ORGANOIDS MARKET, BY COUNTRY, 2020-2032
• 9.5 REST OF THE WORLD
  • 9.5.1 REST OF THE WORLD: IPS CELL-DERIVED ORGANOIDS MARKET, BY COUNTRY, 2020-2032

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 MAJOR GROWTH STRATEGY IN THE GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET
• 10.3 COMPETITOR DASHBOARD

11 COMPANY PROFILES

• 11.1 ACROBIOSYSTEMS
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 MILTENYI BIOTEC
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGIES
• 11.3 THERMOFISHER SCIENTIFIC
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 SWOT ANALYSIS
  • 11.3.6 KEY STRATEGIES
• 11.4 STEMCELL TECHNOLOGIES
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 SWOT ANALYSIS
  • 11.4.6 KEY STRATEGIES
• 11.5 BIO-TECHNE
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCTS OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 KEY STRATEGIES
• 11.6 MERCK KGAA
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 SWOT ANALYSIS
  • 11.6.6 KEY STRATEGIES
• 11.7 MOLECULAR DEVICES, LLC
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 KEY STRATEGIES
• 11.8 CORNING INCORPORATED
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 KEY STRATEGIES
• 11.9 PROMEGA CORPORATION
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS OFFERED
  • 11.9.4 KEY DEVELOPMENTS
  • 11.9.5 KEY STRATEGIES
• 11.10 CREATIVE BIOARRAY
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 KEY STRATEGIES